The global multiplex biomarker imaging market is on the brink of remarkable growth, with forecasts indicating a rise to USD 1,631.4 million by 2034 from USD 585.0 million in 2024, representing a robust compound annual growth rate (CAGR) of 10.8% over the next decade. In 2023, the market generated USD 532.8 million in revenue, highlighting the industry’s strong upward trajectory.
Recent advancements in high-throughput imaging technologies have significantly transformed biomarker analysis, enabling the simultaneous and precise examination of multiple biomarkers. This technological breakthrough is particularly important in the field of diagnostics, where accuracy is critical in addressing complex diseases such as cancer and neurological disorders. Comprehensive biomarker analysis is essential for developing targeted therapies, and the innovations in multiplex biomarker imaging are poised to play a crucial role in enhancing diagnostic precision.
Checkout the Report for Market-Driven Insights
The shift towards personalized medicine further propels demand for sophisticated imaging tools tailored to individual patient profiles. Increased investments in biomedical research and healthcare infrastructure, coupled with strategic collaborations and partnerships, are expected to foster innovation and expand the application scope of biomarker imaging technologies.
“We are witnessing a transformative era in biomarker imaging, driven by technological innovations and a growing demand for personalized healthcare solutions,” said FMI. “The market’s trajectory reflects its critical role in advancing diagnostic capabilities and optimizing treatment outcomes.”
Key Takeaways: Multiplex Biomarker Imaging Market Growth
- The global multiplex biomarker imaging market is expected to reach USD 1,631.4 million by 2034, growing at a CAGR of 10.8%.
- China is projected to be the fastest growing region (CAGR 12.3%) due to rising adoption of digital pathology and telemedicine.
- The US market will see significant growth (CAGR 10.3%) driven by AI and machine learning in image analysis.
- Italy’s market is expected to expand at a CAGR of 10.3% due to advancements in imaging technologies.
- North America (led by Canada) and Asia Pacific (led by China) are key growth regions.
Competitive Landscape:
The competitive landscape of the multiplex biomarker imaging market shows moderate competition, driven by leading companies emphasizing innovation. There are promising investment opportunities in technology and service providers specializing in multiplex biomarker imaging, applied across cancer, immunology, and neurology.
Increasingly, new entrants and strategic partnerships intensify competition, advancing precision medicine through rapid developments in biomarker detection and analysis.
Industry leaders’ company websites and investor presentations are expected to highlight investment potential, aiding in addressing challenges within the multiplex biomarker imaging sector. This support is poised to enhance market share for key industry players.
Recent Industry Developments:
- Illumina Inc. announced in May 2024 that their latest research findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, scheduled from May 31 to June 4. The presentation includes data from multiple studies conducted in collaboration with Labcorp, highlighting additional evidence supporting the advantages of comprehensive genomic profiling (CGP) over single gene testing (SGT). Illumina also showcased new data supporting the ongoing development of their molecular residual disease (MRD) assay. A total of 14 abstracts from Illumina were accepted for presentation at the conference.
- In April 2024, Merck revealed plans to acquire Mirus Bio for USD 600 million. Based in Madison, Wisconsin, Mirus Bio specializes in developing and selling transfection reagents, such as TransIT-VirusGEN®. These reagents facilitate the delivery of genetic material into cells, crucial for producing viral vectors used in cell and gene therapies.
Discover Key Insights – Get A Full Report Immediately
Leading Multiplex Biomarker Imaging Brands:
- PerkinElmer Inc.
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Abcam plc.
- Merck KGaA
- Illumina Inc.
- Leica BiosystemsNussloch GmbH
- Ventana Medical Systems, Inc.
- AushonBioSystems Ltd.
- MicroConstants, Inc.
- ToposNomos Ltd.
Key Segments of the Report:
By Component Type:
The multiplex biomarker imagining industry is classified into instruments (quantitative pathology imaging system, immunofluorescence, multispectral imaging system and toponome imaging system), software and services (installation and integration services and maintenance services).
By Imaging Technique:
The multiplex biomarker imagining industry is classified into Immunohistochemistry (IHC) Assay, Fluorescent in Situ Hybridization (FISH) Assay and Tissue Microarray (TMA) Assay).
By Application:
The multiplex biomarker imagining industry is classified into research and clinical diagnostics.
By End User:
The multiplex biomarker imagining industry is classified into translation laboratories, biopharmaceutical companies and academic institutes.
By Region:
Analysis of the multiplex biomarker imagining industry has been carried out in key countries of North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe and Middle East & Africa.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
